Search results for " Lung disease"

showing 10 items of 102 documents

Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms

2021

Interstitial lung diseases (ILDs) comprise different fibrotic lung disorders characterized by cellular proliferation, interstitial inflammation, and fibrosis. The JAK/STAT molecular pathway is activated under the interaction of a broad number of profibrotic/pro-inflammatory cytokines, such as IL-6, IL-11, and IL-13, among others, which are increased in different ILDs. Similarly, several growth factors over-expressed in ILDs, such as platelet-derived growth factor (PDGF), transforming growth factor β1 (TGF-β1), and fibroblast growth factor (FGF) activate JAK/STAT by canonical or non-canonical pathways, which indicates a predominant role of JAK/STAT in ILDs. Between the different JAK/STAT iso…

QH301-705.5medicine.medical_treatmentReviewCatalysisstatInorganic ChemistryPulmonary fibrosismedicineHumansProtein IsoformsPhysical and Theoretical ChemistryBiology (General)STAT3Molecular BiologyProtein Kinase InhibitorsQD1-999SpectroscopyCellular SenescenceJanus KinasesbiologyChemistryGrowth factorInterleukinsinterstitial lung disease (ILD)Organic ChemistryJAK-STAT signaling pathwayGeneral Medicinerespiratory systemmedicine.diseaseEndoplasmic Reticulum StressComputer Science Applicationsrespiratory tract diseasesSTAT Transcription FactorsChemistrysignal transducer and activator of transcription (STAT)biology.proteinCancer researchidiopathic pulmonary fibrosis (IPF)Janus kinaseLung Diseases InterstitialJanus kinases (JAK)Platelet-derived growth factor receptorTransforming growth factorSignal TransductionInternational Journal of Molecular Sciences
researchProduct

Role of Smads in respiratory disease pathogenesis

2008

Transforming Growth Factor beta (TGFβ) cytokine plays an important role in normal pulmonary morphogenesis and function as well as in the pathogenesis of lung diseases. The principal signaling pathway downstream to activate TGFβ is the Smad pathway. Even though many studies have focused on Smads’ structural features and pathway, less is known about the possible relationship between protein and mRNA expression of Smads and lung diseases. This review will focus on Smads and sum up what is know about their role in some respiratory diseases: COPD,asthma end fibrosis

Settore BIO/16 - Anatomia UmanaTGF-beta1 COPDSmads Lung disease
researchProduct

Role of TGF-b1 in type I collagen production in bronchial epithelial cells: effects on Smad7 inhibitory role?

2008

Airway epithelial cells play an important role in inflammatory, apoptotic and remodelling process associate with fibrosis and COPD. Transforming growth factor 1 (TGF-b1) is involved in airways remodelling by Smads signalling pathway. We investigated the role of TGF-b1 on type I collagen production and Smads (Smad 2-3-4-and 7) expression in bronchial epithelial cells (16HBE). Cells were treated with 1ng/ml and 10ng/ml of TGF-b1 for 0, 3 and 24 hours. With low dose of TGF-b1 we observed no significant variation on Smad2 mRNA expression for both times but a significant increased of Smad7 mRNA expression at 3h (p=0.0043) and a significant reduction of Smad3, Smad4 and Smad7 mRNA expression at 2…

Settore BIO/16 - Anatomia UmanaTGF-beta1 Smads Collagen type I lung disease
researchProduct

Genome-wide association analysis identifies six new loci associated with forced vital capacity

2014

Forced vital capacity (FVC), a spirometric measure of pulmonary function, reflects lung volume and is used to diagnose and monitor lung diseases. We performed genome-wide association study meta-analysis of FVC in 52,253 individuals from 26 studies and followed up the top associations in 32,917 additional individuals of European ancestry. We found six new regions associated at genome-wide significance (P <5 x 10(-8)) with FVC in or near EFEMP1, BMP6, MIR129-2-HSD17B12, PRDM11, WWOX and KCNJ2. Two loci previously associated with spirometric measures (GSTCD and PTCH1) were related to FVC. Newly implicated regions were followed up in samples from African-American, Korean, Chinese and Hispani…

SpirometryLung DiseasesVital capacityQuantitative Trait LociVital CapacityGenome-wide association studyBiologyPolymorphism Single NucleotideArticleDISEASEPulmonary function testingCohort StudiesFEV1/FVC ratioIdiopathic pulmonary fibrosisSDG 3 - Good Health and Well-beingMeta-Analysis as TopicForced Expiratory VolumeDatabases GeneticGeneticsmedicineHumansRestrictive lung diseaseLung volumesGenetic Predisposition to Diseaselung; spriometry; SNP; geneGENE-EXPRESSIONGeneticsmedicine.diagnostic_testGenome HumanHERITABILITYHEALTHY TWINMORTALITYta3141respiratory systemmedicine.diseasePrognosis3. Good healthRespiratory Function Testsrespiratory tract diseasesFAMILYLUNG-FUNCTIONGenetic LociSpirometryImmunologyCELLSIDIOPATHIC PULMONARY-FIBROSISTRAITSFollow-Up StudiesGenome-Wide Association StudyNature Genetics
researchProduct

The Flow-Volume-Measurement in Computer-Supported Lung Function Analysis

1982

For some years computers have been applied more and more in pulmonary function laboratories. On the one hand the medico-technical industry could connect older diagnostic systems with new calculators, on the other hand completely computerised lung function desks have been developed.

Vital capacitymedicine.medical_specialtybusiness.industryDiagnostic systemmedicine.diseaseObstructive lung diseaseComputer supportedPulmonary function testingFlow (mathematics)Volume measurementInternal medicinemedicineCardiologybusinessLung function
researchProduct

Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene…

2018

International audience

[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemMyositis[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemMyopathyInterstitial lung diseaseComputingMilieux_MISCELLANEOUSDermatomyositisAutoantibodies
researchProduct

Drug-induced infiltrative lung disease

2009

International audience; Because the lung manifestations of drugs may be highly variable, a high index of suspicion is required. Both current and past drug intake should be carefully evaluated in any patient with infiltrative lung disease. Drug-induced infiltrative lung disease may manifest as variable clinical radiological patterns, including subacute or chronic interstitial pneumonia, pulmonary fibrosis, eosinophilic pneumonia (presenting as Loffler syndrome, or chronic or acute eosinophilic pneumonia), organising pneumonia, diffuse alveolar haemorrhage, acute respiratory distress syndrome, pulmonary oedema, lipoid pneumonia, alveolar proteinosis or sarcoidosis. A variety of drugs have bee…

drug-inducedinterstitial lung disease[SDV] Life Sciences [q-bio]03 medical and health sciences0302 clinical medicinepulmonary fibrosis030220 oncology & carcinogenesis[SDV]Life Sciences [q-bio]eosinophil030212 general & internal medicineorganising pneumonia3. Good healthalveolar haemorrhage
researchProduct

IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease

2022

ObjectiveSystemic sclerosis (SSc) mortality is extremely variable in its internal organ involvement. Pulmonary fibrosis occurs in up to 30% of the cases. Animal models provide evidence that IL-33 is able to induce both cutaneous and pulmonary fibrosis via increased IL-13 and in SSc patients the levels of IL-33 correlate with skin fibrosis. Our aim was to test whether both IL-33 and IL-13 are higher in patients with diffuse SSc and interstitial lung disease (SSc-ILD) compared to SSc patients without ILD and healthy controls.MethodsSerum levels of IL-13 and IL-33 were measured in 30 SSc patients with diffuse disease and 30 healthy controls by enzyme-linked immunosorbent assay. The extent of p…

interstitial lung diseaseMedicine (General)R5-920interleukinsintegumentary systemsystemic sclerosisIL-13IL-13; IL-33; interleukins; interstitial lung disease; systemic sclerosisIL-33General Medicinerespiratory systemskin and connective tissue diseases
researchProduct

Noninvasive Ventilation in Critically Ill Patients

2015

Since its first application in the late 1980s, noninvasive ventilation (NIV) has been the first-line intervention for certain forms of acute respiratory failure. NIV may be delivered through the patient's mouth, nose, or both using noninvasive intermittent positive pressure ventilation or continuous positive airway pressure. When applied appropriately, NIV may reduce morbidity and mortality and may avert iatrogenic complications and infections associated with invasive mechanical ventilation. This article provides physicians and respiratory therapists with a comprehensive, practical guideline for using NIV in critical care. © 2015 Elsevier Inc.

lung diseaseproceduremedicine.medical_treatmenttreatment indicationtreatment contraindicationReviewCritical Care and Intensive Care MedicineAcute respiratory failureintensive care unitequipment designContinuous positive airway pressureHospital MortalityRespiratory systemNoserisk reductionsleep disorderemergency health serviceRespiratory Distress Syndromeemergency wardcritical illnehumidifierGeneral Medicineadult respiratory distress syndromeIntermittent positive pressure ventilationCritically patientrespiratory circuitmedicine.anatomical_structurepriority journalpositive end expiratory pressureNoninvasive ventilationEmergency Service Hospitalmedicine.medical_specialtyventilatorCritical Illnesswardhypercapnic nonchronic obstructive pulmonary diseasecritically ill patientRespiratory Distress Syndrome Adult Critical Illneobesity hypoventilation syndromemedicineHumansAcute respiratory failurehumanIntensive care medicinelung edemaMechanical ventilationgeneral wardhypoxemiaNoninvasive Ventilationair humidificationCritically illbusiness.industrypractice guidelineRespiratory Distress Syndrome Adultneurally adjusted ventilator assistrespiratory intensive care unitmortalityacute cardiogenic pulmonary edemahypercapnic chronic obstructive pulmonary diseasedisease exacerbationnoninvasive positive pressure ventilationbusinesschronic obstructive lung diseaserespiratory therapeutic device
researchProduct

Lung Transplantation

2014

For patients with terminal lung conditions such chronic obstructive lung disease (COPD), lung transplantation (LuTx) offers treatment to improve quality of life and additionally, in those with certain other diseases—e.g., cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH)—to prolong life (1, 2, e1). It is used at the point when, despite treatment by all available conservative methods, the patient’s quality of life will be clearly impaired or life shortened if transplantation does not take place (3, 4, e2). At present, there are four main surgical options when performing a lung transplantation (5, e3, e4). These are: Unilateral (single lung) …

medicine.medical_specialtyCOPDLungbusiness.industrymedicine.medical_treatmentGeneral Medicinemedicine.diseaseOrgan transplantationObstructive lung diseaseSurgeryTransplantationIdiopathic pulmonary fibrosismedicine.anatomical_structureQuality of lifemedicineLung transplantationIntensive care medicinebusinessDeutsches Ärzteblatt international
researchProduct